Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis

Area of Science:

• Pharmacology
• Nephrology
• Clinical Pharmacy

Background:

• Teicoplanin is an antibiotic used for serious Gram-positive infections.
• Patients with end-stage renal disease often require renal replacement therapy, such as continuous ambulatory peritoneal dialysis (CAPD).
• Understanding teicoplanin's behavior in CAPD patients is crucial for effective dosing and treatment.

Purpose of the Study:

• To investigate the pharmacokinetics of teicoplanin in serum and dialysate.
• To evaluate teicoplanin bioavailability after intraperitoneal administration in CAPD patients.
• To develop a dosing guide for teicoplanin in CAPD patients.

Main Methods:

• A crossover study design was used in five anuric patients undergoing CAPD.
• Teicoplanin was administered intravenously and intraperitoneally at a 3 mg/kg dose.
• Serum and dialysate samples were collected over 30 and 15 days, respectively, and assayed microbiologically.

Main Results:

• After intravenous administration, key pharmacokinetic parameters included a total body clearance of 2.76 +/- 1.08 ml/min and an elimination half-life of 377 +/- 109 hours.
• Only 9% +/- 6% of the intravenous dose was recovered in dialysate, with a net peritoneal clearance of 0.25 +/- 0.21 ml/min.
• Intraperitoneal administration resulted in high bioavailability (0.77-0.78) with a 5-hour dwell time.

Conclusions:

• Teicoplanin exhibits favorable pharmacokinetic properties for intraperitoneal administration in CAPD patients.
• The study provides data to support the development of a teicoplanin dosing guide tailored for CAPD.
• This research aids in optimizing teicoplanin therapy for infections in patients on CAPD.